Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

Conditions

• Diabetes
• Diabetes Mellitus, Type 2

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• semaglutide — DRUG
  Oral administration once daily.
• placebo — DRUG
  Oral administration once daily.

Study Details

This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.

Key Dates

Start date

Sep 20, 2016

Status verified

Jul 2022

Primary completion

Oct 30, 2017

Completion

Dec 8, 2017

Study Design

Enrollment

703 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: 3 mg oral semaglutide
• Experimental: 7 mg oral semaglutide
• Experimental: 14 mg oral semaglutide
• Placebo Comparator: Placebo

Primary Outcome Measure

Change in HbA1c [ Time Frame: Week 0, week 26 ]

Locations (56)

Find similar trials in Lancaster, CA

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Urinary Vitamin C Loss in Diabetic Subjects
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Personalized Environment and Genes Study
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
• Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations
  Enrolling By Invitation · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland